Jan. 5, 2018 Price forecast | 2 weeks: -0.34% | 1 month: -0.89% | 3 months: 5.66%

GTXI stock forecast

Our latest prediction for GTx, Inc.'s stock price was made on the Jan. 5, 2018 when the stock price was at 11.07$.

In the short term (2weeks), GTXI's stock price should underperform the market by -0.34%. During that period the price should oscillate between -9.15% and +19.16%.

In the medium term (3months), GTXI's stock price should outperform the market by 5.66%. During that period the price should oscillate between -21.54% and +40.07%.

Create a solid portfolio with GTXI

Add GTXI to your portfolio and optimize it!

About GTx, Inc.

GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN.

At the moment the company doesn't generate any revenue.

On its last earning announcement, the company reported a loss of -1.86$ per share.

The book value per share is 1.66$

GTx, Inc. website

Three months stock forecastJan. 5, 2018


Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
- - -43M - -42M -1.86 - - 23M 1.66 -39M - -39M